673 related articles for article (PubMed ID: 32036861)
1. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
O'Meara E; McDonald M; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Grzeslo A; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk LM; Moe GW; Swiggum E; Toma M; Virani SA; Zieroth S; De S; Matteau S; Parent MC; Asgar AW; Cohen G; Fine N; Davis M; Verma S; Cherney D; Abrams H; Al-Hesayen A; Cohen-Solal A; D'Astous M; Delgado DH; Desplantie O; Estrella-Holder E; Green L; Haddad H; Harkness K; Hernandez AF; Kouz S; LeBlanc MH; Lee D; Masoudi FA; McKelvie RS; Rajda M; Ross HJ; Sussex B
Can J Cardiol; 2020 Feb; 36(2):159-169. PubMed ID: 32036861
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
3. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
4. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
5. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Packer M; Kitzman DW
JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327
[TBL] [Abstract][Full Text] [Related]
6. Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
S H; Oomman A; Jadhav UM; Raghuraman B; Mohanan PP; Tiwaskar M; Wander GS; Chopra VK
J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082729
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
Dixit NM; Truong KP; Vaduganathan M; Ziaeian B; Fonarow GC
JACC Heart Fail; 2024 Jul; 12(7):1226-1237. PubMed ID: 38703159
[TBL] [Abstract][Full Text] [Related]
8. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
Mareev YV; Mareev VY
Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
[TBL] [Abstract][Full Text] [Related]
9. New pharmacotherapy for heart failure with reduced ejection fraction.
Sotirakos S; Wheen P; Spiers J; Armstrong R
Expert Rev Cardiovasc Ther; 2020 Jul; 18(7):405-414. PubMed ID: 32546023
[TBL] [Abstract][Full Text] [Related]
10. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
Greene SJ; Butler J; Kosiborod MN
Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
Peters AE; DeVore AD
Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
[TBL] [Abstract][Full Text] [Related]
12. Medical Therapies for Heart Failure With Preserved Ejection Fraction.
Kjeldsen SE; von Lueder TG; Smiseth OA; Wachtell K; Mistry N; Westheim AS; Hopper I; Julius S; Pitt B; Reid CM; Devereux RB; Zannad F
Hypertension; 2020 Jan; 75(1):23-32. PubMed ID: 31786973
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
15. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Starr JA; Pinner NA; Lisenby KM; Osmonson A
Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
[TBL] [Abstract][Full Text] [Related]
16. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
[TBL] [Abstract][Full Text] [Related]
17. Reverse Cardiac Remodeling and ARNI Therapy.
Abboud A; Januzzi JL
Curr Heart Fail Rep; 2021 Apr; 18(2):71-83. PubMed ID: 33481182
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
20. What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
Bozkurt B
Curr Cardiol Rep; 2018 Apr; 20(6):39. PubMed ID: 29667019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
